Skip to main content
UniHealth

Doctor search

Rohit Bose, MD

Medical Oncology · San Francisco

NPI 1710140850

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
12
2 carriers
Offices
3
Since medical school
18 years
Graduated 2008

Offices

3 locations · UCSF Medical Group Business Services · University of California San Francisco

Looking this up.

Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.

Plans that list them

12 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bose’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

12 of 12 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

California Medical Board record

Licence A156803 · Current

Licensed to practise in California · since 2018 · expires 2028-07-31 · University of Toronto Faculty of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

  • American Board of Internal Medicine - Medical Oncology

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at UCSF Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths4.9 (3.79 to 6.02) · 7,590 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits12.8 (11.3 to 14.4) · 2,019 casesWorseJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths139.4 (110.22 to 168.58) · 452 casesBetterJul 2022 – Jun 2024
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.622BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.626BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.491BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.8 (0.7 to 1) · 2,336 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.24 (0.58 to 1.9) · 4,689 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.05 (0.89 to 1.2)No differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 89 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.5 · 85 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths10.1 · 132 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.6 · 454 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 618 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 380 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.7 · 5,000 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.22 (0.06 to 0.38) · 15,965 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.2 (0.05 to 0.35) · 17,859 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.85 (0 to 1.83) · 4,184 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2 (1.1 to 2.9) · 6,516 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.35 (4.49 to 10.21) · 3,989 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5 (3.22 to 6.77) · 4,087 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.95 (0.74 to 3.15) · 2,034 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.95 (0.63 to 1.28) · 15,431 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 399 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.899No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.689No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.224No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 156 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20 · 564 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits60.3 · 160 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-9.7 · 550 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits44.1 · 660 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.8 · 667 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.7 (4.8 to 6.7) · 2,019 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6 · 421 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20 · 107 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.9 (11.3 to 17.1) · 3,247 casesNo differentJan 2022 – Dec 2024

What patients said (3,181 patients answered, 25% of those asked)

Patient survey stars by topic at UCSF Medical Center
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at UCSF Medical Center
Room was "always" clean71%
Nurses "always" communicated well80%
Doctors "always" communicated well80%
Staff "always" explained61%
Yes, staff "did" give patients this information88%
Yes, staff "did" give patients information about help after discharge87%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect86%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully78%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night50%
"YES", patients would definitely recommend the hospital81%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$15,388

Medicare paid this office $15,388 for 54 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)49$11,017$116
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's50$1,344$14
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or23$1,114$27

Who their Medicare patients are

54 Original Medicare patients in 2024. Average age 76 · Women 0% · Health risk score 2.38. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: Cancer 75% · High blood pressure 52% · Coronary heart disease 26%.

The office billed $98,374, Medicare allowed $20,955 and paid $15,388; for 249 services of 8 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202454249762.38$98,374$15,388
202343191762.45$80,964$12,884
202263228752.27$114,721$18,759
202163241742.16$140,532$23,298
202065253741.59$181,864$26,369
20181937743.44$17,305$2,660
2017101280763.30$137,800$24,472
20163696753.24$43,420$8,437

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 2 services

Original Medicare services billed in 2023
Long return visit (40+ min)43$8,909$120
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or29$3,076$28

2022: 2 services

Original Medicare services billed in 2022
Long return visit (40+ min)56$13,197$120
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or24$2,645$28

2021: 3 services

Original Medicare services billed in 2021
Long return visit (40+ min)49$15,854$131
New patient visit (60+ min)21$3,209$153
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or30$2,060$29

2020: 3 services

Original Medicare services billed in 2020
Long return visit (40+ min)48$10,700$102
Extended patient service without direct patient contact, first hour41$7,243$103
New patient visit (60+ min)36$5,180$144

2017: 4 services

Original Medicare services billed in 2017
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes52$13,151$93
Return visit (30+ min)35$5,255$68
New patient visit (60+ min)19$2,683$141
Hospital discharge day management, 30 minutes or less19$1,290$64

2016: 1 service

Original Medicare services billed in 2016
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes19$5,054$92

Drugs they prescribed that Part D paid

$631,997

Pharmacies billed $631,997 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 202) in 2024. At or below the middle of the specialty; the typical medical oncology clinician is at 6%.

113 generic and 89 brand-name prescriptions · $631,997 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Xtandi26$355,359$13,668
Orgovyx54$136,912$2,535
Abiraterone Acetate48$72,935$1,519
Prednisone65$166$3

Year by year

Part D prescribing by year
2024202270% (0)44%$631,997
202321429None36%$622,784
202227236None30%$1,011,444
2021585512% (11)30%$2,261,992
2020312334% (13)48%$1,101,606
201823NoneNoneNone$78,683
20174824NoneNone$31,789

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 4 drugs

Part D drugs prescribed in 2023
Erleada17$261,973$15,410
Abiraterone Acetate67$139,379$2,080
Orgovyx52$133,924$2,575
Prednisone58$274$5

2022: 4 drugs

Part D drugs prescribed in 2022
Erleada50$679,989$13,600
Abiraterone Acetate71$159,886$2,252
Orgovyx15$35,277$2,352
Prednisone86$503$6

2021: 5 drugs

Part D drugs prescribed in 2021
Erleada133$1,682,537$12,651
Abiraterone Acetate159$443,797$2,791
Orgovyx17$38,898$2,288
Eliquis13$6,957$535
Prednisone202$1,204$6

2020: 3 drugs

Part D drugs prescribed in 2020
Erleada51$626,295$12,280
Abiraterone Acetate114$474,049$4,158
Prednisone125$559$4

2018: 1 drug

Part D drugs prescribed in 2018
Prednisone11$71$6

2017: 1 drug

Part D drugs prescribed in 2017
Prednisone15$121$8

Money from drug and device companies

$7,720 in 2025

Industry payments by year
2025322$5,681$7,720
202444$818$1,023
202326$4,050$5,616
202212$1,010$1,137
201926None$808

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Janssen BiotechErleada$7,565
20 payments
  • Education for Erleada · 2025-11-10 · $90
  • Meals for Erleada · 2025-06-01 · $121
  • Consulting for Erleada · 2025-05-23 · $1,263
  • Consulting for Erleada · 2025-04-04 · $631
  • Consulting for Erleada · 2025-03-14 · $3,788
  • Travel for Erleada · 2025-03-05 · $46
  • Meals for Erleada · 2025-03-05 · $25
  • Travel for Erleada · 2025-03-05 · $8
  • Travel for Erleada · 2025-03-05 · $216
  • Meals for Erleada · 2025-03-05 · $3
  • Travel for Erleada · 2025-03-05 · $8
  • Meals for Erleada · 2025-03-05 · $54
  • Travel for Erleada · 2025-03-04 · $49
  • Travel for Erleada · 2025-03-04 · $150
  • Travel for Erleada · 2025-03-04 · $263
  • Meals for Erleada · 2025-03-04 · $12
  • Meals for Erleada · 2025-03-04 · $8
  • Meals for Erleada · 2025-03-04 · $8
  • Meals for Erleada · 2025-03-04 · $95
  • Travel for Erleada · 2025-02-25 · $727
ExelixisCabometyx$134
1 payment
  • Meals for Cabometyx · 2025-02-14 · $134
Caris MPIMi Cancer Seek$21
1 payment
  • Meals for Mi Cancer Seek · 2025-06-01 · $21
See all 22 published payments
Every published payment
Janssen BiotechEducation · 2025-11-10Erleada$90
Janssen BiotechMeals · 2025-06-01Erleada$121
Caris MPIMeals · 2025-06-01Mi Cancer Seek$21
Janssen BiotechConsulting · 2025-05-23Erleada$1,263
Janssen BiotechConsulting · 2025-04-04Erleada$631
Janssen BiotechConsulting · 2025-03-14Erleada$3,788
Janssen BiotechTravel · 2025-03-05Erleada$46
Janssen BiotechMeals · 2025-03-05Erleada$25
Janssen BiotechTravel · 2025-03-05Erleada$8
Janssen BiotechTravel · 2025-03-05Erleada$216
Janssen BiotechMeals · 2025-03-05Erleada$3
Janssen BiotechTravel · 2025-03-05Erleada$8
Janssen BiotechMeals · 2025-03-05Erleada$54
Janssen BiotechTravel · 2025-03-04Erleada$49
Janssen BiotechTravel · 2025-03-04Erleada$150
Janssen BiotechTravel · 2025-03-04Erleada$263
Janssen BiotechMeals · 2025-03-04Erleada$12
Janssen BiotechMeals · 2025-03-04Erleada$8
Janssen BiotechMeals · 2025-03-04Erleada$8
Janssen BiotechMeals · 2025-03-04Erleada$95
Janssen BiotechTravel · 2025-02-25Erleada$727
ExelixisMeals · 2025-02-14Cabometyx$134
See earlier years (2024, 2023, 2022, 2019)

2024: $1,023

Payments by company in 2024
Janssen Scientific AffairsErleada$818
1 payment
  • Consulting for Erleada · 2024-08-13 · $818
PfizerOrgovyx$129
1 payment
  • Travel for Orgovyx · 2024-02-02 · $129
Sumitomo Pharma AmericaOrgovyx$54
1 payment
  • Meals for Orgovyx · 2024-10-12 · $54
AstraZeneca Pharmaceuticals LPNone$23
1 payment
  • Meals · 2024-05-31 · $23

2023: $5,616

Payments by company in 2023
PfizerOrgovyx$5,598
5 payments
  • Consulting for Orgovyx · 2023-12-15 · $4,050
  • Meals for Orgovyx · 2023-11-04 · $269
  • Travel for Orgovyx · 2023-11-04 · $720
  • Travel for Orgovyx · 2023-11-04 · $277
  • Travel for Orgovyx · 2023-11-04 · $282
NevroSenza$18
1 payment
  • Meals for Senza · 2023-01-12 · $18

2022: $1,137

Payments by company in 2022
Janssen BiotechErleada$1,137
2 payments
  • Consulting for Erleada · 2022-12-19 · $1,010
  • Meals for Erleada · 2022-02-18 · $127

2019: $808

Payments by company in 2019
GenzymeNo Product Discussed$679
4 payments
  • Travel for No Product Discussed · 2019-10-24 · $43
  • Meals for No Product Discussed · 2019-10-24 · $254
  • Travel for No Product Discussed · 2019-10-24 · $320
  • Travel for No Product Discussed · 2019-10-24 · $62
Janssen BiotechDarzalex$129
2 payments
  • Meals for Erleada · 2019-10-11 · $29
  • Meals for Darzalex · 2019-05-31 · $100

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
74.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1710140850
Licence
CA A156803California A156803: Current · expires 2028-07-31
Group
UCSF Medical Group Business Services · University of California San Francisco
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Medical oncology (207RX0202X)
Mailing address
513 Parnassus Ave # 452, San Francisco, CA, 94143
NPI first listed
2008-07-09
NPI last updated
2019-12-09
NPI record certified
2019-12-09

This is when the NPI record was last certified, not a medical board exam.